SIMONETTI, GIORGIA
 Distribuzione geografica
Continente #
AS - Asia 6.439
NA - Nord America 5.974
EU - Europa 4.537
AF - Africa 381
SA - Sud America 275
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 9
Totale 17.628
Nazione #
US - Stati Uniti d'America 5.874
VN - Vietnam 2.261
SG - Singapore 1.489
CN - Cina 1.434
GB - Regno Unito 1.148
IT - Italia 797
DE - Germania 563
SE - Svezia 563
HK - Hong Kong 383
FR - Francia 297
IN - India 242
NL - Olanda 207
RU - Federazione Russa 200
BR - Brasile 194
IE - Irlanda 170
JP - Giappone 133
KR - Corea 119
FI - Finlandia 101
ZA - Sudafrica 98
TG - Togo 95
UA - Ucraina 95
CI - Costa d'Avorio 78
EE - Estonia 78
BG - Bulgaria 73
CA - Canada 61
NG - Nigeria 61
CH - Svizzera 52
BE - Belgio 50
JO - Giordania 48
PH - Filippine 46
TH - Thailandia 38
AR - Argentina 33
PL - Polonia 30
ID - Indonesia 29
BD - Bangladesh 28
IQ - Iraq 28
ES - Italia 27
AT - Austria 22
MX - Messico 22
SC - Seychelles 22
TW - Taiwan 22
TR - Turchia 21
UZ - Uzbekistan 19
IR - Iran 16
GR - Grecia 15
PK - Pakistan 15
EC - Ecuador 14
AU - Australia 11
CO - Colombia 11
MY - Malesia 10
EU - Europa 9
LT - Lituania 9
EG - Egitto 8
HR - Croazia 8
LB - Libano 8
PY - Paraguay 8
SA - Arabia Saudita 7
AZ - Azerbaigian 5
CL - Cile 5
PE - Perù 5
AE - Emirati Arabi Uniti 4
JM - Giamaica 4
KZ - Kazakistan 4
MA - Marocco 4
MK - Macedonia 4
NP - Nepal 4
PS - Palestinian Territory 4
RO - Romania 4
CZ - Repubblica Ceca 3
GT - Guatemala 3
HN - Honduras 3
HU - Ungheria 3
IL - Israele 3
KE - Kenya 3
KH - Cambogia 3
LV - Lettonia 3
PT - Portogallo 3
RS - Serbia 3
BA - Bosnia-Erzegovina 2
DZ - Algeria 2
ET - Etiopia 2
KG - Kirghizistan 2
KW - Kuwait 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
BH - Bahrain 1
BW - Botswana 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GA - Gabon 1
Totale 17.612
Città #
Singapore 1.061
Southend 994
Dong Ket 772
Ashburn 703
Chandler 541
Fairfield 458
Ho Chi Minh City 374
Hong Kong 359
San Jose 310
Ann Arbor 305
Houston 281
Hanoi 279
Woodbridge 234
Wilmington 233
Seattle 218
Beijing 213
Bologna 210
Hefei 205
Cambridge 187
Princeton 170
Dublin 169
Santa Clara 156
Boardman 155
Tokyo 116
Los Angeles 107
Lomé 95
New York 92
Seoul 88
Lauterbourg 84
Nanjing 84
Westminster 83
Padova 79
Abidjan 78
Helsinki 70
Sofia 69
Medford 60
Munich 57
Milan 53
Da Nang 51
Berlin 50
Haiphong 50
Brussels 49
Buffalo 49
Dallas 48
Abeokuta 46
Amman 46
Jinan 46
Frankfurt am Main 42
Bern 39
Bremen 36
Shenyang 36
Guangzhou 35
Changsha 34
Redondo Beach 34
Redwood City 33
Saint Petersburg 32
Hebei 30
Nanchang 30
Turin 29
Council Bluffs 28
Falls Church 25
Hải Dương 24
Jiaxing 24
Shanghai 24
London 23
San Diego 23
Chicago 22
Florence 22
Paris 21
Amsterdam 20
Jakarta 20
Toronto 20
Turku 20
Bengaluru 19
Jacksonville 19
Biên Hòa 18
Hangzhou 18
Orem 18
Mountain View 17
Montreal 16
São Paulo 16
Tianjin 16
Nuremberg 15
Vienna 15
Baghdad 14
Ningbo 14
Redmond 14
San Francisco 14
Taizhou 14
Warsaw 14
Bangkok 13
Haikou 13
Johannesburg 13
Rome 13
Dearborn 12
Düsseldorf 12
Falkenstein 12
Phoenix 12
Quận Bình Thạnh 12
Zhengzhou 12
Totale 11.358
Nome #
5′UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia 408
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 381
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 311
Network integration of multi-tumour omics data suggests novel targeting strategies 292
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 291
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 289
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 281
Acute myeloid leukemia cell and stem-progenitor cell behavior studied in mimetic bone marrow microenvironment 260
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 258
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 253
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 252
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 249
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 248
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 246
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 235
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 231
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data 231
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 228
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 228
P-206 3D in vitro modelling of relapsed/refractory multiple myeloma to unveil mechanisms of acquired resistance to therapy 226
Fanconi anemia gene variants in therapy-related myeloid neoplasms 215
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 212
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 208
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 207
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 204
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 203
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 200
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 197
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 196
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 193
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 191
A novel Rag2-/- c-/--xenograft model of human CLL 190
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 190
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 188
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 188
Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of IRF4 187
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 186
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 185
Emerging Signatures of Hematological Malignancies from Gene Expression and Transcription Factor-Gene Regulations 184
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 184
Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells 184
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 182
Clec12a: A new AML stem cell-associated antigen 177
HS1 has a central role in the trafficking and homing of leukemic B cells 176
An analysis pipeline for variant discovery in Whole Exome Sequencing data of cancer samples. 175
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 174
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 174
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 174
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 173
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 173
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 172
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 171
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 170
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 169
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions 168
CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies 168
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 167
Impact on the Transcriptome of Proton Beam Irradiation Targeted at Healthy Cardiac Tissue of Mice 165
SNP array reveals a new deletion of JAK2 in AML patients 162
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 161
Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression 160
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 160
Combining Gene Expression Profiling and Integrated Multidisciplinary Approaches to Improve Prognosis Prediction in Multiple Myeloma 158
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 158
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 156
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 154
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 154
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 153
Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels 153
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 152
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 150
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 146
The Irf4 Gene, a Susceptibility Locus for Chronic Lymphocytic Leukemia (CLL), Controls Establishment of Follicular and Marginal Zone B Cell Compartments in Mice 142
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 141
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia 140
Gene expression signature of aneuploidy in acute myeloid leukemia 139
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin 132
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 129
SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders 125
Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells 124
null 123
Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models 123
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions 123
Synthon-approach starting from amino-azaheterocycles to obtain new compounds with potential antiproliferative activity 123
Release of IFNg by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells 121
The role of Toll-like receptors in chronic B cell malignancies 121
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 120
Hemiaminals from amino-azaheterocycles and chloral hydrate as synthons for the access to novel compounds with potential biological activity 115
Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy 113
The diverse roles of IRF4 in late germinal center B-cell differentiation 111
IRF4 controls the positioning of mature B cells in the lymphoid microenvironments by regulating NOTCH2 expression and activity 108
Germinal center B cell maintenance and differentiation are controlled by distinct NF- B transcription factor subunits 107
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study 100
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 100
Novel Mouse Models of Chronic Lymphocytic Leukemia (CLL) Unravel the Molecular Mechanisms Controlling Bone Marrow Involvement by Leukemic B Cells 94
The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells 91
Potential CDC20 inhibitors: synthesis and biological evaluation of Apcin analogues 89
Differential Expression and Non-Redundant Functions of NF-kappa B Transcription Factor Subunits in Germinal Center (GC) B Cell Subpopulations 89
Rearrangements of ATP5L‐KMT2A in acute lymphoblastic leukaemia 79
Patient and carer involvement in the formulation of research questions: findings from the Italian guideline on palliative care in adults with glioma 77
Totale 17.794
Categoria #
all - tutte 44.900
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.900


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.124 0 0 0 0 0 0 0 0 0 65 93 966
2021/20221.892 253 55 109 185 191 94 46 101 84 101 351 322
2022/20232.182 238 310 122 301 176 178 58 109 365 57 167 101
2023/2024654 22 99 32 84 41 159 38 57 32 39 22 29
2024/20252.413 62 347 227 147 251 78 267 113 29 270 137 485
2025/20265.704 597 498 453 401 609 278 560 228 1.604 476 0 0
Totale 17.967